{
    "clinical_study": {
        "@rank": "36778", 
        "arm_group": [
            {
                "arm_group_label": "Seretide Diskus and charcoal", 
                "arm_group_type": "Active Comparator", 
                "description": "Single-dose of Seretide Diskus (50/500 mcg/inhalation) and charcoal"
            }, 
            {
                "arm_group_label": "Seretide Diskus", 
                "arm_group_type": "Active Comparator", 
                "description": "Single-dose of Seretide Diskus (50/500 mcg/inhalation)"
            }, 
            {
                "arm_group_label": "SF Easyhaler and charcoal", 
                "arm_group_type": "Experimental", 
                "description": "Salmeterol/fluticasone Easyhaler (50/500 mcg/inhalation) with charcoal"
            }, 
            {
                "arm_group_label": "SF Easyhaler", 
                "arm_group_type": "Experimental", 
                "description": "Salmeterol/fluticasone Easyhaler (50/500 mcg/inhalation)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the test product Salmeterol/fluticasone Easyhaler\n      with the reference product Seretide Diskus in terms of drug absorbed in the bloodstream."
        }, 
        "brief_title": "Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol/Fluticasone Easyhaler With Seretide Diskus", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy males and females aged 18-60 years\n\n          -  Normal weight, at least 50 kg\n\n        Exclusion Criteria:\n\n          -  Evidence of clinically significant cardiovascular, renal, hepatic, haematological,\n             GI, pulmonary, metabolic-endocrine, neurological or psychiatric disease\n\n          -  Any clinically significant abnormal laboratory value or physical finding that may\n             interfere with the interpretation of study results or constitute a health risk for\n             the subject if he/she takes part in the study\n\n          -  Any condition requiring regular concomitant treatment (including vitamins and herbal\n             products) or likely to need any concomitant treatment during the study\n\n          -  Known hypersensitivity to the active substance(s) or the excipient of the drug\n\n          -  Pregnant or lactating females"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01856621", 
            "org_study_id": "3106008 EudraCT 2012-003782-18"
        }, 
        "intervention": [
            {
                "arm_group_label": "Seretide Diskus and charcoal", 
                "description": "2 inhalations as a single dose", 
                "intervention_name": "Seretide Diskus and charcoal", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Seretide Diskus", 
                "description": "2 inhalations as a single dose", 
                "intervention_name": "Seretide Diskus", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "SF Easyhaler and charcoal", 
                "description": "2 inhalations as a single dose", 
                "intervention_name": "SF Easyhaler and charcoal", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "SF Easyhaler", 
                "description": "2 inhalations as a single dose", 
                "intervention_name": "SF Easyhaler", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Charcoal", 
                "Salmeterol", 
                "Fluticasone", 
                "Fluticasone, salmeterol drug combination"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 2, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Espoo", 
                    "country": "Finland"
                }, 
                "name": "Orion Pharma Clinical Pharmacology Unit"
            }
        }, 
        "location_countries": {
            "country": "Finland"
        }, 
        "number_of_arms": "4", 
        "official_title": "Pharmacokinetic Study Comparing Two Salmeterol Fluticasone Propionate Device-metered Dry Powder Inhalers, Salmeterol/Fluticasone Easyhaler and Seretide Diskus 50/500 Mcg/Inhalation; a Randomised, Doubleblind,Single Centre, Single Dose, Crossover Study in Healthy Subjects", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Finland: Finnish Medicines Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetic parameter Cmax of plasma salmeterol concentration", 
                "safety_issue": "No", 
                "time_frame": "Within 34 h"
            }, 
            {
                "measure": "Pharmacokinetic parameter Cmax of plasma fluticasone propionate concentration", 
                "safety_issue": "No", 
                "time_frame": "Within 34 h"
            }, 
            {
                "measure": "Pharmacokinetic parameter AUCt of plasma salmeterol concentration", 
                "safety_issue": "No", 
                "time_frame": "Within 34 h"
            }, 
            {
                "measure": "Pharmacokinetic parameter AUCt of plasma fluticasone propionate concentration", 
                "safety_issue": "No", 
                "time_frame": "Within 34 h"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01856621"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Orion Corporation, Orion Pharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Orion Corporation, Orion Pharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}